GLP1R and metabolic dysfunction-associated steatotic liver disease: These drugs not only facilitate weight loss but also contribute to reducing liver inflammation and fibrosis.[135] For instance, liraglutide has shown promise in enhancing nonalcoholic steatohepatitis histology and decelerating fibrosis progression in the “Liraglutide Efficacy and Action in Diabetes” (LEAD) study, while semaglutide has also exhibited potential in NAFLD treatment.[136,137] Despite these encouraging results, many GLP-1 RAs still require thorough investigation for NAFLD treatment, necessitating additional clinical trials to confirm their effectiveness.[135]